...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New trial
Reply New Message
Prev Message Back To Forum Threaded View Next Message

You think Zenith would push all the NCI trials to at least the conclusion of phase 2 before entertaining a buyout? (assuming success in phase 1)

We've been in a couple of Phase II studies for quite a while now so I don't know what it will take.  

 

2 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply